复旦张江(688505) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was ¥140,724,701, a decrease of 23.99% compared to the same period last year, and a year-to-date revenue of ¥548,848,564, down 22.47% year-on-year[2]. - The net profit attributable to shareholders for the third quarter was ¥15,995,540, a decline of 25.44%, with a year-to-date net profit of ¥86,468,604, down 3.81% year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for the third quarter was ¥10,822,388, a decrease of 34.74%, with a year-to-date figure of ¥54,500,468, down 23.76% year-on-year[2]. - Total operating revenue for the first three quarters of 2024 was RMB 548,848,564, a decrease of 22.5% compared to RMB 707,960,683 in the same period of 2023[16]. - Net profit for the first three quarters of 2024 was RMB 86,171,568, a slight decrease of 4.6% compared to RMB 89,811,290 in the same period of 2023[17]. - Basic and diluted earnings per share for the first three quarters were both RMB 0.08, down from RMB 0.09 in the previous year[18]. Research and Development - Research and development (R&D) expenses totaled ¥79,540,074 for the third quarter, an increase of 56.79%, with year-to-date R&D expenses of ¥234,870,223, up 38.71% year-on-year[4]. - The ratio of R&D expenses to operating revenue was 56.52% for the third quarter, an increase of 29.12 percentage points, and 42.79% year-to-date, up 18.87 percentage points year-on-year[4]. - Research and development expenses increased significantly to RMB 235,745,108, up 40% from RMB 168,541,486 in the previous year[16]. Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date was -¥60,152,607, a significant decrease of 3,613.16% year-on-year[4]. - Cash flow from operating activities showed a net outflow of RMB 60,152,607, contrasting with a net inflow of RMB 1,712,208 in the same period last year[20]. - The net increase in cash and cash equivalents was -157,352,803, compared to -46,840,367 in the previous period[21]. - The ending balance of cash and cash equivalents was 1,038,543,194, down from 1,242,462,297 in the previous period[21]. - The company paid 91,127,687 in dividends and interest, an increase from 74,615,047 in the previous period[21]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,627,120,117, a decrease of 8.68% compared to the end of the previous year[4]. - The company's current assets totaled RMB 1,656,774,707, down from RMB 1,869,424,886, indicating a decrease of about 11.35%[13]. - Total liabilities decreased to RMB 274,499,573 from RMB 518,124,139, a significant reduction of about 47.14%[14]. - The company's equity attributable to shareholders was RMB 2,351,908,069, slightly down from RMB 2,357,553,851, a decrease of about 0.24%[14]. Shareholder Information - The company has a total of 20,006 shareholders, with 19,870 holding A shares and 136 holding H shares[11]. - The largest shareholder, Shanghai Pharmaceutical Group Co., Ltd., holds a total of 210,142,560 shares, including 139,578,560 A shares and 70,564,000 H shares[11]. Other Financial Metrics - The weighted average return on net assets was 0.68%, a decrease of 0.24 percentage points for the quarter, and 3.66% year-to-date, down 0.25 percentage points[4]. - Total operating costs decreased to RMB 490,043,765, down 18.4% from RMB 600,143,402 year-on-year[16]. - Sales expenses decreased to RMB 173,777,581, down 47.9% from RMB 333,644,772 year-on-year[16]. - Tax expenses increased to RMB 5,299,582, compared to RMB 3,893,911 in the same period of 2023[16]. - Other comprehensive income after tax showed a loss of RMB 222,673, compared to a loss of RMB 164,801 in the previous year[18]. Investment Activities - Total cash inflow from investment activities was RMB 3,069,165,185, slightly up from RMB 3,056,147,909 in the previous year[20]. - The company reported a total cash outflow from investing activities of 3,091,638,335, compared to 3,068,186,518 in the previous period[21]. - Cash flow from investing activities totaled 3,068,186,518, with a net cash flow of 978,667, compared to a negative cash flow of 35,490,426 in the previous period[21]. Accounting Standards - The company is not applying the new accounting standards for the current reporting period[22].